Tourmaline Bio/TRML

$13.45

3.15%
-
1D1W1MYTD1YMAX

About Tourmaline Bio

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company. The Company is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. It is also developing TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional diseases under consideration. It is focused on two strategic paths for TOUR006, the first of which it refers to as FcRn+. Its second strategic path is cardiovascular inflammation.

Ticker

TRML

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sandeep Kulkarni

Employees

44

Headquarters

New york, United States

Tourmaline Bio Metrics

BasicAdvanced
$345M
Market cap
-
P/E ratio
-$5.35
EPS
-
Beta
-
Dividend rate
$345M
$48.31
$9.18
437K
62.171
-12.39%
-12.77%
-12.75%
0.974
0.974
71.59%

What the Analysts think about Tourmaline Bio

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
333.68% upside
High $74.00
Low $48.00
$13.45
Current price
$58.33
Average price target

Tourmaline Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$13M
-733.33%
Profit margin
0%
NaN%

Tourmaline Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 17.71%
QuarterlyAnnual
Q4 22
Q1 23
Q4 23
Q1 24
Q2 24
Actual
-$4.40
-$5.40
-$0.81
-$0.55
-
Expected
-$4.90
-$3.50
-$0.79
-$0.67
-$0.71
Surprise
-10.2%
54.29%
2.53%
-17.71%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Tourmaline Bio stock?

Tourmaline Bio (TRML) has a market cap of $345M as of May 28, 2024.

What is the P/E ratio for Tourmaline Bio stock?

The price to earnings (P/E) ratio for Tourmaline Bio (TRML) stock is 0 as of May 28, 2024.

Does Tourmaline Bio stock pay dividends?

No, Tourmaline Bio (TRML) stock does not pay dividends to its shareholders as of May 28, 2024.

When is the next Tourmaline Bio dividend payment date?

Tourmaline Bio (TRML) stock does not pay dividends to its shareholders.

What is the beta indicator for Tourmaline Bio?

Tourmaline Bio (TRML) does not currently have a Beta indicator.

What is the Tourmaline Bio stock price target?

The target price for Tourmaline Bio (TRML) stock is $58.33, which is 338.9% above the current price of $13.29. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Tourmaline Bio stock

Buy or sell Tourmaline Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing